Jpmorgan Chase & CO Alaunos Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$0.04 - $0.13 $1,820 - $5,917	-45,519 Reduced 99.56%	201 $0
Q3 2023 Nov 14, 2023	SELL	$0.12 - $0.5 $290,042 - $1.21 Million	-2,417,020 Reduced 98.14%	45,720 $5,000
Q2 2023 Aug 11, 2023	SELL	$0.43 - $0.65 $23,514 - $35,545	-54,686 Reduced 2.17%	2,462,740 $1.26 Million
Q1 2023 May 11, 2023	BUY	$0.46 - $0.81 $386 - $681	841 Added 0.03%	2,517,426 $1.59 Million
Q4 2022 Feb 13, 2023	SELL	$0.5 - $261.0 $4,329 - $2.26 Million	-8,658 Reduced 0.34%	2,516,585 $1.63 Million
Q3 2022 Nov 14, 2022	SELL	$1.04 - $322.5 $1.76 Million - $546 Million	-1,693,239 Reduced 40.14%	2,525,243 $4.34 Million
Q2 2022 Aug 11, 2022	BUY	$0.41 - $1.24 $384,594 - $1.16 Million	938,036 Added 28.59%	4,218,482 $5.23 Million
Q1 2022 May 11, 2022	SELL	$0.62 - $1.17 $237,322 - $447,851	-382,779 Reduced 10.45%	3,280,446 $2.14 Million
Q4 2021 Feb 10, 2022	SELL	$1.09 - $1.89 $9,998 - $17,336	-9,173 Reduced 0.25%	3,663,225 $3.99 Million
Q3 2021 Nov 12, 2021	BUY	$1.44 - $2.73 $5.29 Million - $10 Million	3,672,398 New	3,672,398 $6.69 Million

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $458M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.